Organization
NSLIJHS, Lake Success, NY
4 abstracts
Abstract
4 YEAR EXPERIENCE OF BELIMUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY, IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Org: OMRF, OK City, OK, NSLIJHS, Lake Success, NY, Cedars-Sinai UCLA, Los Angeles, CA, OK Ctr for Arth Ther & Res, Tulsa, OK, SUNY Downstate, Brooklyn, NY,
Abstract
BELIMUMAB, A BLYS-SPECIFIC INHIBITOR, REDUCES DISEASE ACTIVITY AND SEVERE FLARES IN SEROPOSITIVE SLE PATIENTS: BLISS-76 STUDY Org: The Karolinska Institute, Stockholm, Sweden, Rheuma Zentrum Favoriten, Vienna, Austria, David Geffen School of Medicine, Cedars-Sinai–UCLA, West Hollywood, CA, United States, Inst of Rheumatology, Prague, Czech Republic, OMRF, Oklahoma City, OK,
Abstract
BELIMUMAB (FULLY HUMAN MONOCLONAL ANTIBODY TO BLYS) IMPROVED OR STABILIZED SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE ACTIVITY AND REDUCED FLARE RATE DURING 3 YEARS OF THERAPYOrg: NSLIJHS, Lake Success, NY, Lake Success, NY, JHU, Baltimore, Cedars-Sinai Comprehensive Cancer Center,
Abstract
BELIMUMAB (FULLY HUMAN MONOCLONAL ANTIBODY TO BLYS) REDUCED STEROID USE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS DURING 3 YEARS OF THERAPYOrg: SUNY Downstate, Brooklyn, NY, Cedars-Sinai UCLA, Los Angeles, CA, Univ of AL at Birmingham, Birmingham, AL, OK Center for Arthritis Therapy and Research, Tulsa, NSLIJHS, Lake Success, NY,